ASCO	American Society of Clinical Oncology
BSC	best supportive care
BTC	biliary tract cancer
CCA	cholangiocarcinoma
CI	confidence interval
CTLA-4	cytotoxic T-lymphocyte-associated protein-4
eCCA	extrahepatic cholangiocarcinoma
FDA	United States Food and Drug Administration
FGFR	fibroblast growth factor receptor
GBCA	gallbladder carcinoma
dMMR	mismatch repair deficiency
iCCA	intrahepatic cholangiocarcinoma
IDH	isocitrate dehydrogenase
FU	fluoropyrimidine
HR	hazard ratio
IT	immunotherapy
ITT	intention to treat
MMR	mismatch repair
mOS	median overall survival
MSI	microsatellite instability
mRFS	median recurrence-free survival
ORR	overall response rate
OS	overall survival
PD-1	programmed cell death protein-1
PD-L1	programmed cell death protein-1 ligand 1
QOL	quality of life
RFS	recurrence-free survival
TKI	tyrosine kinase inhibitor
vs.	versus